Differential occupancy of somatodendritic and postsynaptic 5HT1A receptors by pindolol: A dose-occupancy study with [11C]WAY 100635 and Positron Emission Tomography in humans

Neuropsychopharmacology

Volumn 24, Issue 3, 2001, Pages 209-229

  Martinez, Diana ^a,b   Hwang, Dah Ren ^a,b   Mawlawi, Osama ^a,b   Slifstein, Mark ^a,b   Kent, Justine ^a,b   Simpson, Norman ^a,b   Parsey, Ramin V ^a,b   Hashimoto, Tomoki ^a,b   Huang, Yiyun ^a,b   Shinn, Ann ^a,b   Van Heertum, Ronald ^a,b   Abi Dargham, Anissa ^a,b   Caltabiano, Stephen ^c   Malizia, Andrea ^c   Cowley, Hugh ^c   Mann, J John ^a,b   Laruelle, Marc ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Mood disorders; Pindolol; Positron emission tomography; SSRI

Indexed keywords

CARBON 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PINDOLOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

CONTROLLED RELEASE FORMULATION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW;

EID: 0035128641     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00187-1     Document Type: Article

References (94)

1. 123I]iomazenil: Kinetic and equilibrium paradigms
2. 11C]NNC 112 in humans: Validation and reproducibility
3. Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets
4. Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus
5. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography
6. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
7. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
8. Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy
9. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: An in vivo microdialysis study
10. Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum
11. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial
12. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial
13. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression
14. Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors
15. Current advances and trends in the treatment of depression
16. Pharmacokinetics of beta-adrenoceptor blocking agents: Clinical significance of hepatic and/or renal clearance
17. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial
18. Parameters estimation in positron emission tomography
19. Affinity of (±)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre- and postsynaptic serotonin 5-HT(1A) receptors in human and rat brain
20. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain
21. 3H]spiperone binding: Evidence for accumulation in corpus striatum by agonist-mediated receptor internalization
22. Estrogen enhances a 5-HT1A response in hippocampal slices from female rats
23. Lack of 5-hydroxytrytamine1A-mediated inhibition of adenylyl cyclase activity in dorsal raphe male and female rats
24. Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo
25. Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain
26. Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: Effects of age and alcohol
27. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors
28. PET imaging of serotonin 1A receptor binding in depression
29. Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins
30. [H-3]Alnespirone: A novel specific radioligand of 5-HT1A receptors in the rat brain
31. PET-characterization of [carbonyl-C-11]WAY-100635 binding to 5-HT1A receptors in the primate brain
32. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man
33. The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro
34. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635
35. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil
36. Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: An in vivo microdialysis and electrophysiological study
37. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: Comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors
38. 3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes
39. The putative 5-HT1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro
40. 11C]WAY-100635 for PET
41. Modulation of the firing activity of rat serotonin and noradrenaline neurons by (+/-)pindolol
42. 11C]WAY-100635
43. Differentiation of pre- and post-synaptic high affinity serotonin receptor binding sites using physico-chemical parameters and modifying agents
44. Pindolol occupancy of 5HT(1A) receptors measured in vivo using small animal positron emission tomography with carbon-11 labelled WAY 100635
45. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine
46. Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptors: Behavioural and in vivo brain microdialysis studies
47. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites
48. 5-HT receptors: Subtypes and second messengers
49. 11C-carbonyl]WAY 100635
50. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex
51. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
52. Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome
53. D with the opiate antagonist cyclofoxy: Equilibrium studies in the conscious rat
54. Analysis of emission tomographic scan data: Limitations imposed by resolution and background
55. An interactive procedure for extracting features of the brain from magnetic resonance images: The lobes
56. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review
57. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters
58. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. I. Kinetic modeling of single bolus experiments
59. 2 receptors in healthy subjects
60. A method for the solution of certain problems in least squares
61. Dose- and time-dependent binding and kinetics of pindolol in patients with congestive heart failure
62. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance
63. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression
64. Effects of imipramine on raphe nuclei and prefrontal cortex extracellular serotonin levels in the rat
65. Performance characteristics of a head immobilization device for PET imaging
66. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents
67. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists
68. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography
69. Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors
70. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: Comparison of the behavior of an identified radioactive metabolite with parent radioligand in monkey using PET
71. PET studies of competition between [11C]carbonyl-WAY 100635 and endogenous serotonin
72. Validation and reproducibility of measurement of 5-HT1A receptors parameters with [carbonyl-11C]WAY-100635 in humans: Comparison of arterial and reference tissue input functions
73. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
74. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors
75. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635
76. Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: Implications for antidepressant therapy
77. Pharmacological and physicochemical properties of pre-versus postsynaptic 5-hydroxytryptamine1A receptor binding sites in the rat brain: A quantitative autoradiographic study
78. Displacement of the binding of 5-HT(1A) receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain
79. 8-OH-DPAT internalizes 5HT1A autoreceptors in serotonin neurons of nucleus raphe dorsalis
80. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain
81. Analysis of the mechanism of internalization of the human 5HT1A receptor
82. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment
83. Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo
84. Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT1 receptor
85. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists
86. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: A comparative study with dorsal raphe neurons
87. Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: Single-unit study in unanesthetized, unrestrained rats
88. Paroxetine and pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency
89. 5HT(1A) receptor agonist antagonist binding affinity difference as a measure of intrinsic affinity in recombinant and native tissue systems
90. Rapid automated algorithm for aligning and reslicing PET images
91. How long should pindolol be associated with paroxetine to improve the antidepressant response?
92. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study